trial · primary record
Tazemetostat
Diffuse Large B-cell Lymphoma (DLBCL)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 58 |
| Primary completion | 2025-09-26 |
| Primary endpoint | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) |
| Registry ID | NCT02875548 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:28.659Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02875548
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.